Another phase II trial is underway to determine the effects of combining pembrolizumab with anti-VEGF receptor (ramucirumab), and docetaxel in treating NSCLC patients who failed to respond to FDA-approved treatments with platinum-based chemotherapy administered concurrently or sequentially with anti-PD-1/PD-L1 immunotherapy (NCT04340882). Here, CD274 is linked to non-small cell lung carcinoma.